Showing 381-390 of 3239 results for "".
- Survey: Many Skip Yearly Derm Visitshttps://practicaldermatology.com/news/survey-many-skip-yearly-derm-visits/2461306/Many folks are avoiding the dermatologist and other specialists, according to a nationwide survey of more than 1,050 people by Myvision.org Fully 48 percent of survey respondents don’t remember the last time they went to the dermatologist, and only 10 percent
- First Patient Enrolled in UNION Therapeutic’s Study of Orismilast MR tablet in ADhttps://practicaldermatology.com/news/first-patient-enrolled-in-union-therapeutics-study-of-orismilast-mr-tablet-in-ad/2461288/The first patient has been enrolled in ADESOS, a Phase 2b dose-finding study evaluating the safety and efficacy of UNION therapeutic’s orismilast MR tablet in adult patients with moderate to severe AD. The purpose of the study is to identify the appropria
- Aesthetics Biomedical Adds to Leadership Team to Fuel Growth Trajectoryhttps://practicaldermatology.com/news/aesthetics-biomedical-adds-to-leadership-team-to-fuel-growth-trajectory/2461280/In an ongoing efforts to meet the increasing demand for its aesthetic products and distribution growth, Aesthetics Biomedical Inc. (ABM), is continuing to build its executive team with the recent hires of industry experts Derek Harmon as Vice President of U.S. Sales and Don Selvey, NMD, MS as Vic
- Dermaliq Forms New Scientific and Medical Advisory Boardhttps://practicaldermatology.com/news/dermaliq-forms-new-scientific-and-medical-advisory-board/2461270/Dermaliq Therapeutics, Inc. has formed a Scientific and Medical Advisory Board. New members include Gordon Dow, Xavier Yon, Michael Kuligowski, MD, PhD, and R. Todd Plott, MD. The Advisory Board is composed of key clinical investigators and industry veterans in the field who suppor
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a
- The Skin Cancer Foundation Raises $625,000 For Skin Cancer Education Programs at Annual Galahttps://practicaldermatology.com/news/the-skin-cancer-foundation-raises-625000-for-skin-cancer-education-programs-at-annual-gala/2461200/The Skin Cancer Foundation Champions for Change Gala raised $625,000 in support of the organization’s educational campaigns, community programs and research initiatives. More than 300 guests attended the event, including Skin Cancer Foundation donors, industry and physician
- Curél Gives Back: Skincare Brand Supports Nurseshttps://practicaldermatology.com/news/curel-gives-back-skincare-brand-supports-nurses/2461187/Through Curél Cares, Curél will be donating to the American Nurses Foundation and treating several highly deserving nurses to an all-expenses-paid pampering trip to New York City. In addition, Curél will also sponsor the half-day American Nurses Associati
- Pathologist Survey: Melanoma Is Overdiagnosedhttps://practicaldermatology.com/news/pathologist-survey-melanoma-is-overdiagnosed/2461180/Many pathologists agree that overdiagnosis of skin cancer happens, but don’t change diagnosis behavior, according to a new study. “Overdiagnosis is the diagnosis of disease that will not harm a person in their lifetime. If melanoma is being overdiagnosed, it means that too m
- Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Diseasehttps://practicaldermatology.com/news/ready-for-prime-time-ampels-blood-tests-may-predict-drug-options-for-inflammatory-skin-disease/2461179/Ampel BioSolutions machine learning approach can characterize disease activity from gene expression data obtained from patient skin biopsy and may revolutionize the way doctors treat inflammatory skin diseases, according to research published in Science Advances. The lab test
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn